Parnax Lab (BOM:506128) Short-Term Debt: ₹ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506128 Parnax Lab Ltd BOM:506128
69 GF Score
Price ₹128.25
GF Value ₹149.51
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Parnax Lab Short-Term Debt?

Parnax Lab BOM:506128 +1.21% 69 Short-Term Debt is ₹ Mil as of Jun. 2026. GuruFocus rates BOM:506128 with a GF Score™ of 69/100 and a GF Value™ of ₹149.51 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Parnax Lab's Short-Term Debt for the quarter that ended in Jun. 2026 was ₹ Mil.

Parnax Lab's quarterly Short-Term Debt increased from Dec. 2025 (₹ Mil) to Mar. 2026 (₹534 Mil) but then declined from Mar. 2026 (₹534 Mil) to Jun. 2026 (₹ Mil).

Parnax Lab's annual Short-Term Debt declined from Mar. 2024 (₹507 Mil) to Mar. 2025 (₹433 Mil) but then increased from Mar. 2025 (₹433 Mil) to Mar. 2026 (₹534 Mil).

Parnax Lab Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Parnax Lab Short-Term Debt Related Terms

Parnax Lab Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Parnax Lab's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parnax Lab Short-Term Debt Chart

Parnax Lab Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial 485.07 393.85 506.97 432.84 533.65

Parnax Lab Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 422.53 - 533.65 -
BOM:506128
69GF Score
Parnax Lab Ltd BOM:506128
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹ Mil mean?
Parnax Lab (BOM:506128) has a Short-Term Debt of ₹ Mil as of Jun. 2026.
Is Parnax Lab's Short-Term Debt too high?
Parnax Lab's current Short-Term Debt is ₹ Mil. Overall, Parnax Lab has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Parnax Lab's Short-Term Debt compare to ZTS?
Parnax Lab's Short-Term Debt of ₹ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Parnax Lab's current Short-Term Debt is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parnax Lab stock overvalued right now?
Based on GuruFocus' analysis, Parnax Lab (BOM:506128) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.51, compared to a current price of ₹128.25 — trading 14.2% below its estimated fair value. The current Short-Term Debt is ₹ Mil. Parnax Lab's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Parnax Lab (BOM:506128), the current Short-Term Debt is ₹ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Parnax Lab (BOM:506128) Overvalued in 2026?

Based on GuruFocus' analysis, Parnax Lab stock appears to be undervalued. The current stock price of ₹128.25 is trading 14.2% below its estimated GF Value™ of ₹149.51. GuruFocus considers Parnax Lab to be Modestly Undervalued.

Key valuation signals for BOM:506128:

  • Short-Term Debt: ₹ Mil
  • GF Value™: ₹149.51 vs. price of ₹128.25 (14.2% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the BOM:506128 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Parnax Lab Business Description

Other Exchanges PARNAXLAB:India
Address INS Towers, G-Block, BKC, 1109/1110 ‘A’ Wing, INS Tower, G Block, Bandra Kurla Complex, Bandra East, Mumbai, MH, IND, 400051
Parnax Lab Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and export of pharmaceutical formulations. Its product portfolio spans oral liquid formulations such as cough expectorants, antacids, antihistamines, multivitamins, enzyme preparations, pediatric and geriatric formulations, suspensions, and highly viscous products, alongside cosmetics, herbal, and nutraceutical offerings. The company operates manufacturing facilities in India and serves both domestic and international markets, exporting formulations to customers in various countries. Its revenue is derived primarily from the sale of finished pharmaceutical and healthcare products, with contract manufacturing and export operations forming significant components of its business. Parnax Lab caters to pharmaceutical companies, healthcare distributors, and institutional buyers, positioning itself as a formulation-focused manufacturer with capabilities in liquid and specialty oral dosage forms.
69GF Score

Get the complete analysis for BOM:506128

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹128.25
Price
₹149.51
GF Value